PMPRB Consults on Proposed Practice Directions for PMPRB Hearings

Why It Matters

These updates aim to accelerate price‑excessiveness and filing‑compliance hearings, lowering costs for pharmaceutical firms while enhancing regulatory transparency.

Key Takeaways

• Paper hearings default for evidentiary submissions
• Electronic filing and page limits standardize written briefs
• AI use must be disclosed in all hearing documents
• Virtual oral arguments become routine, with exceptions
• Expedited FTF process targets 90‑day resolution

Pulse Analysis

The Patented Medicine Prices Review Board, Canada’s regulator of patented drug pricing, is confronting a wave of digital transformation and procedural bottlenecks. By issuing seven draft Practice Directions, the PMPRB signals a shift toward streamlined, technology‑enabled hearings that mirror broader trends in administrative law. The emphasis on paper‑based evidentiary submissions paired with virtual oral arguments reflects a hybrid model designed to preserve the rigor of documentary review while leveraging the convenience of remote participation. This approach also aligns with global best practices that prioritize accessibility and cost efficiency.

Key provisions such as mandatory electronic filing, strict page limits, and a uniform affidavit‑based document exchange aim to reduce administrative overhead for both the board and market participants. Requiring parties to disclose any artificial‑intelligence assistance in drafting submissions introduces a transparency safeguard, pre‑empting potential challenges over authenticity or bias. The expedited failure‑to‑file (FTF) pathway, with its 90‑day timetable, directly addresses the lengthy delays that can stall price‑review decisions, offering a faster resolution for rights‑holders who miss filing deadlines. Collectively, these measures promise a more predictable and faster adjudication environment.

For pharmaceutical companies and patent holders, the proposed changes could translate into measurable savings and clearer timelines for price‑excessiveness assessments. Faster hearings reduce the window of regulatory uncertainty, enabling firms to allocate resources more efficiently and maintain market stability. Moreover, the AI disclosure rule may spur internal governance upgrades, ensuring that emerging technologies are used responsibly. As the PMRB finalizes these directions, stakeholders should prepare by updating filing protocols, training counsel on AI declaration requirements, and integrating electronic submission workflows to stay compliant and capitalize on the anticipated procedural efficiencies.